BIVI - Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioVie Inc. (BIVI) | Benzinga
LOS ANGELES, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming March 19, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired BioVie Inc. ("BioVie" or the "Company") (NASDAQ:BIVI) securities between August 5, 2021 through November 29, 2023, inclusive (the "Class Period").
If you suffered a loss on your BioVie investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at www.glancylaw.com/cases/BioVie-Inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.
On November 8, 2023, BioVie disclosed that, for the Phase 3 clinical trial of its Alzheimer's treatment, NE3107, the Company had "uncovered what appears to be potential scientific misconduct and significant non-compliance with [Good Clinical Practices ("GCPs")] and regulation at six sites," which "may call into question the rigor, robustness and validity of the entire data set for [the study] and may require additional clinical studies to confirm the final results[.]"
On this news, BioVie's stock price fell $1.25, or 29.3%, to close at $3.01 per share ...
BIVI)>Full story available on Benzinga.com